<DOC>
	<DOC>NCT02515942</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of 12 (every 28 days) intravitreal (IVT) injections of CLG561 as a monotherapy and in combination with LFG316 as compared to sham in subjects with geographic atrophy.</brief_summary>
	<brief_title>CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)</brief_title>
	<detailed_description>This study consists of an up-to 30-day screening period, an approximately 336-day treatment period, and a follow-up period consisting of two visits occurring 4 and 16 weeks after the last administered injection.</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Sign written informed consent form; Geographic atrophy in both eyes; Other protocolspecified inclusion criteria may apply. Pregnant or lactating women and women of childbearing potential; Any medical condition (systemic or ophthalmic) that may preclude the safe administration of test article or safe participation in this study; Any contraindications or hypersensitivities to any component of the LFG316 or CLG561 solution; Any contraindications to IVT injections; Ocular surgery in either eye within 90 days of screening; Uncontrolled ocular hypertension or glaucoma in the study eye; Other protocolspecified exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>